Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
A Phase II Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma
Sponsor: David Bond, MD
No open prediction endpoints
Endpoints are classified and published by ProgramSignal analysts.
Request endpoint coverageKey Facts
Primary Endpoints (CT.gov)
Complete remission (CR) rate
Time frame: At the end of Cycle (each cycle is 28 days)
Secondary Endpoints
Overall response rate (ORR)
Progression free survival
Incidence of adverse events
Eligibility Criteria
Inclusion Criteria: * Adult patient (age 18 or older) * Willing and able to provide written informed consent for the trial, assent when appropriate may be obtained per institutional guidelines * Eastern Cooperative Oncology Group (ECOG) performance status =\< 2 * Considered transplant eligible by the treating physician * Measurable disease by CT (defined as \>= 1.5 cm in diameter) or one or more area of PET avid disease * Have received one line of prior chemo-immunotherapy (i.e. cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine \[R-CHOP\]). Note that corticosteroids for palliation of symptoms and radiation consolidation are not considered a line of therapy for purposes of eligibility determination * Eligible histologic diagnosis includes: Diffuse large B cell lymphoma not otherwise specified (NOS), T cell histiocyte rich large B cell lymphoma, primary mediastinal B Cell lymphoma, follicular lymphoma grade 3B, high grade B cell lymphoma with MYC and BCL2 and/or BCL6 …
Read full criteria on CT.gov →✦ Analyst Commentary
Expert commentary on why this trial matters and what to watch for.
Request coverage →